These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24997148)

  • 21. Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients.
    Akrawinthawong K; Chaowalit N; Chatuparisuth T; Siritanaratkul N
    Hematology; 2011 Mar; 16(2):113-22. PubMed ID: 21418744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart Rate Variability for Early Detection of Iron Overload Cardiomyopathy in β-Thalassemia Patients.
    Koonrungsesomboon N; Tantiworawit A; Phrommintikul A; Saekho S; Srichairattanakool S; Chattipakorn N
    Hemoglobin; 2015; 39(4):281-6. PubMed ID: 26029793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre.
    Belhoul KM; Bakir ML; Kadhim AM; Dewedar HE; Eldin MS; Alkhaja FA
    Ann Saudi Med; 2013; 33(1):18-21. PubMed ID: 23458935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia.
    Chern JP; Lin KH
    J Pediatr Hematol Oncol; 2002 May; 24(4):291-3. PubMed ID: 11972098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia.
    Musallam KM; Motta I; Salvatori M; Fraquelli M; Marcon A; Taher AT; Cappellini MD
    Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):136-9. PubMed ID: 22727143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major.
    Aubart M; Ou P; Elie C; Canniffe C; Kutty S; Delos V; Graffigne C; de Montalembert M; Brousse V
    J Pediatr Hematol Oncol; 2016 Oct; 38(7):497-502. PubMed ID: 27548334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron-chelating therapy for transfusional iron overload.
    Musallam KM; Taher AT
    N Engl J Med; 2011 Apr; 364(15):1476; author reply 1477. PubMed ID: 21488787
    [No Abstract]   [Full Text] [Related]  

  • 28. A decisional algorithm to start iron chelation in patients with beta thalassemia.
    Danjou F; Cabantchik ZI; Origa R; Moi P; Marcias M; Barella S; Defraia E; Dessì C; Foschini ML; Giagu N; Leoni GB; Morittu M; Galanello R
    Haematologica; 2014 Mar; 99(3):e38-40. PubMed ID: 24598857
    [No Abstract]   [Full Text] [Related]  

  • 29. Association of frequency of hereditary hemochromatosis (HFE) gene mutations (H63D and C282Y) with iron overload in beta-thalassemia major patients in Pakistan.
    Sharif Y; Irshad S; Tariq A; Rasheed S; Tariq MH
    Saudi Med J; 2019 Sep; 40(9):887-892. PubMed ID: 31522215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.
    Voskaridou E; Douskou M; Terpos E; Papassotiriou I; Stamoulakatou A; Ourailidis A; Loutradi A; Loukopoulos D
    Br J Haematol; 2004 Sep; 126(5):736-42. PubMed ID: 15327528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current management of thalassemia intermedia].
    Thuret I
    Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracellular iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients.
    Shaw J; Chakraborty A; Nag A; Chattopadyay A; Dasgupta AK; Bhattacharyya M
    Eur J Haematol; 2017 Nov; 99(5):399-408. PubMed ID: 28815805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
    Al-Khabori M; Bhandari S; Al-Rasadi K; Mevada S; Al-Dhuhli H; Al-Kemyani N; Daar S
    Hemoglobin; 2014; 38(5):365-8. PubMed ID: 25074643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of iron overload on impaired fertility in male patients with transfusion-dependent beta-thalassemia.
    Chen MJ; Peng SS; Lu MY; Yang YL; Jou ST; Chang HH; Chen SU; Lin DT; Lin KH
    Pediatr Res; 2018 Mar; 83(3):655-661. PubMed ID: 29166371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of growth differentiation factor 15 (GDF15) polymorphisms with serum GDF15 and ferritin levels in β-thalassemia.
    Athiyarath R; George B; Mathews V; Srivastava A; Edison ES
    Ann Hematol; 2014 Dec; 93(12):2093-5. PubMed ID: 24867648
    [No Abstract]   [Full Text] [Related]  

  • 37. Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major.
    Wahidiyat PA; Wijaya E; Soedjatmiko S; Timan IS; Berdoukas V; Yosia M
    Blood Cells Mol Dis; 2019 Jul; 77():67-71. PubMed ID: 30978615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T2* MRI in regularly transfused children with thalassemia intermedia: serum ferritin does not reflect liver iron stores.
    Tony S; Daar S; Elshinawy M; Al-Zadjaly S; Al-Khabori M; Wali Y
    Pediatr Hematol Oncol; 2012 Sep; 29(6):579-84. PubMed ID: 22839111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy.
    Chirico V; Lacquaniti A; Salpietro V; Luca N; Ferraù V; Piraino B; Rigoli L; Salpietro C; Arrigo T
    Eur J Endocrinol; 2013 Dec; 169(6):785-93. PubMed ID: 24014554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.